The cystic fibrosis (CF) airways are colonized by polymicrobial communities with high bacterial load and are influenced by frequent antibiotic exposures. This community includes diverse streptococci, some of which have been directly or indirectly associated with pulmonary exacerbations. As many streptococci are naturally competent, horizontal transfer of antibioticresistant determinants coupled with frequent and/or chronic antibiotic exposure may contribute to high resistance rates. In this study, we assessed antibiotic resistance in 413 streptococcal isolates from adult CF patients against nine antibiotics relevant in CF treatment. We observed very low rates of cephalosporin resistance [cefepime and ceftriaxone (,2 %)], and higher rates of resistance to tetracycline (,34 %) and sulfamethoxazole/trimethoprim (,45 %). The highest rate of antibiotic resistance was to the macrolides [azithromycin (56.4 %) and erythromycin (51.6 %)]. We also investigated the molecular mechanisms of macrolide resistance and found that only half of our macrolide-resistant streptococci isolates contained the mef (efflux pump) or erm (methylation of 23S ribosomal target site) genes. The majority of isolates were, however, found to have point mutations at position 2058 or 2059 of the 23S ribosomal subunit -a molecular mechanism of resistance not commonly reported in the non-pyogenic and non-pneumococcal streptococci, and unique in comparison with previous studies. The high rates of resistance observed here may result in poor outcomes where specific streptococci are contributing to CF airway disease and serve as a reservoir of resistance genes within the CF airway microbiome.
The cystic fibrosis (CF) airways are colonized by polymicrobial communities with high bacterial load and are influenced by frequent antibiotic exposures. This community includes diverse streptococci, some of which have been directly or indirectly associated with pulmonary exacerbations. As many streptococci are naturally competent, horizontal transfer of antibioticresistant determinants coupled with frequent and/or chronic antibiotic exposure may contribute to high resistance rates. In this study, we assessed antibiotic resistance in 413 streptococcal isolates from adult CF patients against nine antibiotics relevant in CF treatment. We observed very low rates of cephalosporin resistance [cefepime and ceftriaxone (,2 %)], and higher rates of resistance to tetracycline (,34 %) and sulfamethoxazole/trimethoprim (,45 %). The highest rate of antibiotic resistance was to the macrolides [azithromycin (56.4 %) and erythromycin (51.6 %)]. We also investigated the molecular mechanisms of macrolide resistance and found that only half of our macrolide-resistant streptococci isolates contained the mef (efflux pump) or erm (methylation of 23S ribosomal target site) genes. The majority of isolates were, however, found to have point mutations at position 2058 or 2059 of the 23S ribosomal subunit -a molecular mechanism of resistance not commonly reported in the non-pyogenic and non-pneumococcal streptococci, and unique in comparison with previous studies. The high rates of resistance observed here may result in poor outcomes where specific streptococci are contributing to CF airway disease and serve as a reservoir of resistance genes within the CF airway microbiome.
INTRODUCTION
Cystic fibrosis (CF) is characterized by chronic microbial infections within the lower respiratory tract (Gilligan, 2014; LiPuma, 2010) . It is now well established that the CF airways harbour a complex microbiota in addition to classical pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae and the Burkholderia cepacia complex (Dickson et al., 2013; Lynch & Bruce, 2013; Rabin & Surette, 2012; Rogers et al., 2015; Surette, 2014) , and diverse commensal streptococci (LiPuma, 2012; Lynch & Bruce, 2013; Rogers et al., 2010; Sibley et al., 2006) , some of which may become pathogenic (Parkins et al., 2008; Sibley et al., 2008a Sibley et al., , 2009 Sibley et al., , 2010 .
Furthermore, other streptococci isolated from CF sputum can act synergistically with P. aeruginosa to enhance pathogenicity within polymicrobial infections (Duan et al., 2003; Sibley et al., 2008b) , at least in part by increasing P. aeruginosa virulence gene expression (Sibley et al., 2008b) .
Modern clinical interventions to increase airway clearance and improved antibiotic therapy have reduced the rate of respiratory function decline and increased CF patient survival (Maeda et al., 2011) . However, the CF patient population is at greater risk for harbouring antibiotic-resistant isolates due to chronic antibiotic treatment. Some of these drugs have poor penetration to the site of action within the lungs and achieve inadequate dosage of drugs, thereby facilitating induction of antibiotic resistance (Honeybourne, 1994) . Confounding this, many streptococci have the ability to readily acquire antibiotic resistance determinants through natural competence (Cook & Federle, 2014; Fontaine et al., 2014) .
Within the non-pyogenic/viridans streptococci, high levels of resistance to b-lactams and fluoroquinolones have been documented (Diekema et al., 2001; Gordon et al., 2002; Smith et al., 2004) . One study observed that 32 % of nonpyogenic streptococci were non-susceptible (defined as intermediate and/or resistant profiles) to penicillin, with Streptococcus mitis isolates displaying the greatest resistance (Doern et al., 1996; Paulus et al., 2009) . In addition, isolates with penicillin resistance display higher MICs to other b-lactams, such as cephalosporins, relative to penicillinsensitive isolates (Alcaide et al., 1995) . It was reported that 12 % of Canadian and 5 % of European isolates of pneumococci are resistant to penicillin, much of which is attributed to horizontal transfer of penicillin-binding protein genes among other streptococci (Chi et al., 2007) .
Macrolide, clindamycin and tetracycline resistance rates in non-pyogenic streptococci have risen rapidly. Macrolide resistance is particularly high within the non-pyogenic streptococci, with 30 % of isolates in North America and 80 % in Eastern Asia considered as non-susceptible (Chen et al., 2009; de Azavedo et al., 2001; Diekema et al., 2003; Felmingham et al., 2007) . Macrolide-resistant isolates can emerge quickly, as shown in healthy individuals placed on either azithromycin or clarithromycin for 1 week and the subsequent emergence of macrolide-resistant streptococci (Kastner & Guggenbichler, 2001 ). Macrolide resistance rates in non-pyogenic streptococci typically range from 20 to 50 %, with the highest rates found within the S. mitis group, in particular Streptococcus pneumoniae. In Canada, prevalence increased from 8 % in 1998 to 22 % in 2008 (Wierzbowski et al., 2014) . Furthermore, with the ability of recombination and genetic exchange between closely related species, such as S. mitis, S. pneumoniae and Streptococcus oralis (Håvarstein et al., 1997) , the potential of acquiring resistance determinants is high and may be a contributing factor for increasing resistance rates. CF patients may receive chronic azithromycin as it has been shown to reduce exacerbation frequency, increase weight gain and reduce lung function decline depending on co-infecting pathogens (Saiman et al., 2003 (Saiman et al., , 2010 ) that further promote resistance in these organisms. In one study of CF patient isolates, 95 % of non-pyogenic streptococci isolated from the lower respiratory tract were macrolide non-susceptible, with 80 % amongst those demonstrating resistance (Tazumi et al., 2009) . In another study, the Streptococcus anginosus group (comprised of S. anginosus, Streptococcus intermedius and Streptococcus constellatus) isolated from adult CF patients demonstrated a fivefold increased risk of azithromycin resistance in CF over non-CF isolates . In this study, 85 % of the S. anginosus group isolates from patients exposed to azithromycin were macrolide-resistant .
The potential future efficacy of antibacterial interventions in CF may be limited by emerging antibiotic resistance, particularly important in an ageing patient population exposed to the selective pressure of life-long antibiotic therapy. The streptococci are abundant within the CF microbiome, and contribute to the antibiotic resistome with the ability for natural competence to acquire and disseminate resistance determinants. To evaluate rates of antibiotic resistance across this heterogeneous group of organisms, we sought to observe susceptibility profiles from isolates obtained from adult CF patients. Antibiotics were selected for those that are clinically used in CF treatment, including azithromycin, tetracycline, cefepime, ceftriaxone, clindamycin, tetracycline and sulfamethoxazole/ trimethoprim. Furthermore, we sought to characterize the molecular mechanism(s) driving the high level of resistance previously observed in the CF-derived S. anginosus group.
METHODS
Bacterial strains and growth conditions. A total of 413 isolates were obtained from 68 adult CF patients during times of either clinical stability or acute exacerbation (Table 1 ). These isolates were collected over a 5-year period from 2006 to 2011. Patients were included on the basis of having at least three isolates within our cultured CF collection. Prior macrolide exposure history was documented for each patient. The methodology of growth, isolation and identification by 16S rRNA sequencing follows work described previously (Sibley et al., 2008a) . Those isolates that had a partial 16S rRNA identification of S. mitis, S. oralis or S. pneumoniae were categorized together as the S. mitis group due to the similarity of the partial sequence. Those isolates identified as Streptococcus vestibularis, Streptococcus thermophilus or Streptococcus salivarius were categorized together as the S. salivarius group. Additionally, those isolates with partial 16S rRNA identification v97 % identity threshold were classified as Streptococcus spp. Isolates were prospectively collected and frozen in 10 % skim milk. They were then recovered to either Brain Heart Infusion (BHI) agar (Difco) or Columbia Blood Agar (CBA; Difco) with the addition of 5 % defibrinated sheep blood (Dailynn) and incubated at 37 uC with 5 % CO 2 for 24-48 h prior to disc diffusion assays.
Antimicrobial disc diffusion assay. The 413 isolates underwent antimicrobial disc diffusion assays for nine drugs clinically relevant in CF . Data corresponding to the S. anginosus group isolates were published previously . Isolates were subcultured from frozen milk stocks at 280 uC to CBA containing 5 % defibrinated sheep blood (Med-Ox) and incubated at 37 uC in a 5 % CO 2 incubator for 24 h. The quality control strain S. pneumoniae ATCC 49619 was grown as above. Mueller-Hinton Blood Agar (MHBA; Difco) containing 5 % defibrinated sheep blood (MedOx) was prepared according to Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI, 2009a, b) . The following antimicrobial discs were stamped with a disc dispenser or manually placed and read as per CLSI guidelines: penicillin G (10 U), ceftriaxone (30 mg), cefepime (30 mg), ceftazidime (30 mg), azithromycin (15 mg), erythromycin (15 mg), clindamycin (2 mg), tetracycline (30 mg) and sulfamethoxazole/trimethoprim (25 mg). For sulfamethoxazole/trimethoprim, we used EUCAST breakpoints for Streptococcus pyogenes/Streptococcus agalactiae (EUCAST, 2015) . Isolates that had been classified as intermediate or resistant were grouped together and denoted as 'non-susceptible' for subsequent analysis.
PCR amplification of antibiotic resistance determinants (mefA/E, ermB and ermTR). All isolates underwent PCR screening for the antibiotic resistance determinants mefA/E, ermB and ermTR. A DNA template was prepared by boiling lysis. Amplification reactions and cycles for mefA/E and ermB were as described by Amezaga et al. (2002) . PCR amplification of ermTR was performed as described previously (Kataja et al., 1998) . Reaction mixtures consisted of 5 ml 10| PCR buffer (Invitrogen), 1.5 ml MgCl 2 (50 mM), 8 ml dNTPs (1.25 mM each), 1 ml forward primer TR-F (10 pmol ml 21 ), 1 ml reverse primer TR-R (10 pmol ml 21 ), 0.25 ml Taq (5 U ml 21 ) and 5 ml DNA template for a final volume of 50 ml. The amplification program was an initial denaturation of 94 uC for 5 min, followed by 30 cycles of 94 uC for 30 s, 42 uC for 60 s and 72 uC for 90 s, followed by a final extension at 72 uC for 10 min. Ten amplicons were sent for sequencing at the University of Calgary DNA sequencing facility using the forward primer for quality control. The remainder of the PCR products were viewed by electrophoresis for presence of the mefA/E, ermB or ermTR genes.
Detection of 23S rRNA point mutations by PCR and sequencing.
A conserved region of the 23S rRNA subunit was used from annotated genomes to construct primer sets. Those isolates that were found to be macrolide-resistant but did not contain mef/erm resistance determinants, apart from the S. anginosus group isolates that were described previously , underwent PCR amplification for the conserved region of the 23S rRNA gene. The reaction conditions were: 5 ml 10| PCR buffer (Invitrogen), 1.5 ml MgCl 2 (50 mM), 8 ml dNTPs (1.25 mM each), 1 ml 23SF1 primer (59-GAGAACTCTCGTTAAGGAACTCG-39) (10 pmol ml 21 ), 1 ml 23SR1 primer (59-TAAGTCCACTCTGGTCCTCTCG-39) (10 pmol ml 21 ), 0.25 ml Taq (5 U ml
21
) and 5 ml DNA template prepared by boiling lysis for a final reaction volume of 50 ml. The amplification program was an initial denaturation of 95 uC for 5 min, followed by 30 cycles of 95 uC for 45 s, 60 uC for 30 s and 72 uC for 60 s, followed by a final extension at 72 uC for 10 min. PCR product sizes of 950 bp were obtained and sequenced at Macrogen using the forward primer 23SF1. For reference, the middle A nucleotide of the sequence GGAAAGA is position 2059 in E. coli (equivalent to nt 2061 in S. pneumoniae). Mutations at nt 2058 or 2059 (E. coli numbering) which are known to confer macrolide resistance were identified.
Ethical approval. Ethical approval for this work was granted by the Conjoint Health Regional Ethics Board of the University of Calgary (E23087).
RESULTS

Antibiotic resistance in streptococci isolated from CF sputum
To examine the streptococci resistance profiles, 413 streptococci isolates obtained from 68 adult CF patients were characterized (Table 1 ). The S. salivarius group (S. salivarius, S. thermophilus and S. vestibularis) represented the largest collection of streptococci at 103 isolates. The Streptococcus spp., comprising novel species, subspecies or biotypes, represented 11.6 % (48/413) of the clinical isolates from 25 patients (C. S. Thornton and others, manuscript in preparation). Approximately half of the clinical isolates (228/413; 55.2 %) originated from patients that were on chronic azithromycin therapy, as defined by continuous treatment time i3 months.
Unlike a large percentage of the S. anginosus group, which showed inadequate growth on the test medium MHBA Antibiotic resistance in Streptococcus from CF patients , the other streptococci isolates in this study had uniform growth on MHBA. The distribution of zone sizes for the nine antibiotics of the isolates is shown in Fig. 1 . A diverse distribution of zone sizes was found for all antibiotics tested, displaying a heterogeneous antibiotic profile. Seven of the nine antibiotics and a combination of treatment (sulfamethoxazole/ trimethoprim) tested had breakpoint values available for the non-pyogenic streptococci and were further used to assess levels of antibiotic resistance in these isolates (Table 2) .
Third-and fourth-generation cephalosporin resistance levels were low in all isolates tested, with only 1.1 % resistance to both ceftriaxone and cefepime (Table 2 ). In contrast, 32 % of all isolates were resistant to tetracycline. Those species that showed the greatest percentages of non-susceptible isolates to tetracycline were The combination of sulfamethoxazole/trimethoprim is frequently used in the adult CF patient population, from which this strain collection was obtained. We observed that 45.3 % of isolates were not susceptible to sulfamethoxazole/trimethoprim. Susceptibility was lowest in the S. mitis group (45 %) and highest in the S. anginosus group (80.5 %). A large number of patients harboured at least one sulfamethoxazole/trimethoprim-resistant isolate, but resistance was more prevalent in patients that had received chronic azithromycin therapy (114/210, 54 %) versus those that had not (42/117, 34 %) (Table 3) . Given this, it was not surprising that w80 % of sulfamethoxazole/trimethoprim-resistant isolates were also macrolide-resistant. However, the opposite relationship was not observed (i.e. macrolide-resistant strains were equally likely to be sulfamethoxazole/trimethoprimsensitive or -resistant).
Multidrug resistance
A large percentage of multidrug-resistant isolates (nonsusceptibility to two or more classes of antibiotics) was observed for all of the streptococcal species tested (Table 2) . Multidrug resistance was strikingly high amongst the Streptococcus spp., observed in 91.7 % (44/48) of isolates. Unlike other members of the S. anginosus group, S. intermedius was amongst the species with the lowest percentage of multidrug-resistant isolates (11/32, 34.8 %). Multidrug-resistant isolates were also present in every patient listed in Table 3 . Amongst those on chronic azithromycin therapy, 84.2 % of isolates showed multidrug resistance, whilst 72.1 % of isolates from patients who were not on chronic azithromycin therapy showed multidrug resistance. The difference was not statistically significant between the two groups; however, it should be noted that the elevated levels of multidrug-resistant isolates amongst all CF patients in this study are likely an outcome of life-long multi-class antibiotic use in the adult population. A summary of the distribution of multidrug resistance for the strains listed in Table 3 is presented in Fig. 2 . The cephalosporins and b-lactam class of antibiotics were omitted from Fig. 2 because of their low prevalence in this study. We found 12 % of isolates were resistant to all four classes of antibiotics presented here, similar to the 12.3 % that were sensitive to all antibiotics. *Data for S. constellatus, S. anginosus and S. intermedius were obtained previously . DMultidrug resistance as defined by isolates resistant to two or more classes of antibiotic. dMultidrug resistance as defined by isolates resistant to two or more classes of antibiotic.
Mechanisms of macrolide resistance
The high levels of macrolide resistance observed, in conjunction with approximately half of our patient population on chronic azithromycin therapy, prompted us to elucidate the molecular mechanism(s) of resistance (Table 4 , Fig. 3a) . Amongst the macrolide-resistant isolates, only 52.3 % possessed genes for one of the commonly identified antibiotic resistance determinants: mefA/E (macrolide efflux pump), ermB or ermTR (methylation of 23S ribosome target site). Specifically, carriage of these determinants (amongst all macrolide-resistant isolates) was: 29.6 % for mefA/E, 18.8 % for ermB and 3.8 % for ermTR. The single macrolide-resistant Streptococcus mutans isolate was found to have both mefA/E and ermB. mefA/E was the most prevalent resistance determinant in S. parasanguinis (9/17, 52.9 %) and the S. salivarius group (30/61, 49.2 %), whilst ermB was most prevalent in S. intermedius (6/11, 54.5 %), S. anginosus (9/26, 34.6 %), S. parasanguinis (5/17, 29.4 %), Streptococcus sanguinis (6/21, 28.9 %) and the S. salivarius group (13/61, 21.3 %). Of the 10 isolates harbouring ermTR, five were S. anginosus.
The remaining macrolide-resistant isolates (47.6 %) that did not yield PCR products for the aforementioned resistance determinants were found to have a point mutation within the 23S rRNA subunit at position 2058 or 2059, i.e. the macrolide target site. Ribosomal mutations were the only mechanism of macrolide resistance identified in S. constellatus (n526), but also accounted for 79.5 % of the Streptococcus spp. (31/39). Point mutation A2058G was the most common (69/124, 55.6 %) and was most prevalent in isolates belonging to the S. anginosus group: S. anginosus (38.5 %), S. constellatus (76.9 %) and S. intermedius (27.3 %). In contrast, A2058G and A2058T were equally prevalent in Streptococcus spp. (33.3 % and 43.6 %, respectively). Point mutation A2059G was only detected in S. constellatus (5/26), the S. mitis group (1/41) and Streptococcus spp.
(1/39). The distribution of macrolide resistance determinants is highlighted in Fig. 3(a) . It is clear that 23S mutation is the predominant mechanism of macrolide resistance in S. constellatus and Streptococcus spp., and represents nearly half of S. sanguinis, S. intermedius, S. anginosus and S. mitis group isolates. However, mefA/E and ermB were the predominant mechanisms of macrolide resistance observed in S. parasanguinis, the S. salivarius group and Streptococcus infantis.
To assess the distribution of macrolide resistance determinants in patients, profiles from isolates were grouped according to patient and then patients were divided on the basis of chronic azithromycin therapy (Fig. 3b) . All isolates from patients on chronic azithromycin therapy had some degree of 23S-based resistance, including two patients where this was the only macrolide resistance determinant identified. Three of the 11 patients who were not on chronic azithromycin therapy did not yield any macrolide-resistant isolates with a 23S mutation, but rather had mefA/E or ermB as the macrolide resistance determinants. The sensitive/resistance distribution (by mechanisms) in all of the isolates from the two groups is summarized in Fig. 3(c) .
DISCUSSION
Antibiotics are very commonly used in CF therapy. The non-pyogenic streptococci have been traditionally viewed as commensal organisms; however, evidence of the clinical significance of these microbes is emerging (Doern & Burnham, 2010) . Due to their genomic plasticity, and the presence of frequent and chronic antibiotic exposure within CF patients, this provides an opportune niche for the presence of an antibiotic resistome.
Predictably, antibiotic resistance was prevalent within the spectrum of Streptococcus spp. Consistent with other published reports on CF microbial resistance, macrolide resistance was prevalent in the CF isolates Tazumi et al., 2009) . Ceftazidime has been used effectively to treat P. aeruginosa but is thought to have poor activity against members of the streptococci, although in our study the majority of isolates were susceptible (Alcaide et al., 1995; Stelzmueller et al., 2007) . Tetracycline resistance was consistent with published values, with the high resistance rates observed likely a consequence of the frequent use of tetracyclines in CF (Gó mez-Garcés et al., 1994; Grinwis et al., 2010; Limia et al., 1999) .
Sulfamethoxazole/trimethoprim resistance was observed in nearly half of the isolates. Although generally considered an effective anti-pseudomonal treatment, it has previously been noted that many CF isolates of P. aeruginosa are insensitive to this combination therapy (Qin et al., 2012; Richards et al., 1998) . This antibiotic combination is generally effective against Staphylococcus aureus (Goss & Muhlebach, 2011 Fig. 2 . Summary of the distribution of single-antibiotic-and multidrug-resistant isolates within this study. The percentage of total isolates for each single or combination of resistance profiles is shown. Cephalosporins and penicillin were omitted from this analysis as they represent only a small proportion of the total isolates (,3 %). SXT, sulfamethoxazole/trimethoprim.
Antibiotic resistance in Streptococcus from CF patients used in the treatment of streptococcal infections, recent studies have suggested they may be a valid alternative for the treatment of S. pyogenes soft-tissue infections (Bowen et al., 2012) . That study reported very low rates of trimethoprim resistance; however, streptococcal resistance to trimethoprim and sulfamethoxazole/trimethoprim has been reported (Bergmann et al., 2014; Soeters et al., 2012) . A survey of pneumococcal isolates from South Africa found a correlation between sulfamethoxazole/trimethoprim resistance and resistance to other classes of antibiotics, including macrolides (Soeters et al., 2012) . We did not examine susceptibility to sulfamethoxazole and trimethoprim independently; however, it is known that the S. anginosus group is resistant to sulfamethoxazole (Poole & Wilson, 1976) . These two antibiotics target two different steps in tetrahydrofolate biosynthesis and it is thought that the combination therapy will reduce the emergence of resistance. As the S. anginosus group is already intrinsically sulfamethoxazole-resistant (Poole & Wilson, 1976) , it might have been expected that the members may have acquired trimethoprim resistance more readily, but this does not appear to be the case.
The mechanisms of macrolide resistance observed in this study were unexpected and contrasted with predominant mechanisms published previously (Tazumi et al., 2009) . Non-pyogenic streptococci antibiotic resistance determinants typically arise from two mechanisms: the mef and erm classes of genes. mef-mediated macrolide resistance encompasses active drug efflux and provides resistance towards only the macrolide class, referred to as the M phenotype (Felmingham et al., 2007; Gordon et al., 2002) . erm-mediated macrolide resistance involves target site modification by erythromycin resistance methylases, and can provide cross-resistance to macrolides, lincosamides and streptogramin B (otherwise referred to as the MLS phenotype) that may be constitutively or inducibly expressed (Leclercq & Courvalin, 1991; Tazumi et al., 2009) . Tazumi et al. (2009) surveyed a group of streptococci from adult CF patients with screening for molecular characterization of macrolide resistance determinants. All the streptococci isolates were found to contain either erm or mef classes of genes (Tazumi et al., 2009) . However, we found that nearly half of our isolates contained one of two point mutations within the 23S ribosomal subunit target site and no mef or erm gene. Although not assessed in this study, ribosomal point mutations have been described in Streptococcus spp. within domains II and V of the 23S rRNA, and in genes encoding riboproteins L4 and L22 (Farrell et al., 2004) . Recent studies of macrolide resistance in S. pneumoniae indicated that these mutations were present in 3.3 % of 865 resistant isolates in a Canadian study (Wierzbowski et al., 2007) , none of 76 isolates in a Russian study (Reinert et al., 2008) and in three of 20 in another study (Tait-Kamradt et al., 2000) . 23S rRNA mutations have also been shown to lead to resistance against macrolides and streptogramin B, and are referred to as the MS phenotype (Tazumi et al., 2009) . A2058G was the predominant point mutation within the isolates. The different point mutations and number of alleles mutated may contribute to altered MIC ranges, as has been shown previously (Farrell et al., 2004) . The high rate of 23S mutations found in S. constellatus is of interest as most of these strains are the pharyngitis subspecies and have lost the ability to undergo natural competence (M. E. Grinwis, A. M. Lacroix and M. G. Surette, unpublished) . The abundance of isolates with 23S ribosomal mutations thus raises several possibilities. Differences in clinical treatment and therapy at our CF site may result in the variability within macrolide resistance. Additionally, expression of mutated and non-mutated alleles within isolates in response to antimicrobial exposure may be relevant in the therapy given. Geographical distribution of antibiotic resistance determinants has been observed, such as the majority of macrolide resistance in North America accounted for by mef, whilst in Europe the erm phenotype dominates in streptococci (Farrell et al., 2002) .
Point mutations within the 23S ribosomal subunit may benefit the microbes beyond antibacterial resistance, and this may include immune evasion tactics. Oldenburg et al. (2012) demonstrated that acquisition of antibiotic resistance factors led to immune evasion by Toll-like receptor (TLR)-13. Resistance to the MLS group of antibiotics mediated by site-specific methylation of position A2058 in isolates with erythromycin resistance rendered 23S rRNA non-stimulatory to TLR-13, with a reduction of macrophage activation and subsequent lower levels of serum cytokine. The observation of 23S rRNA modifications contributing to immune evasion may be especially relevant in CF patients who experience immune dysregulation and chronic microbial infection. The high levels of streptococci isolates presenting with point mutations at position A2058 may reflect additional selective pressures that lead to attenuation of the immune response in CF patients. As TLR-13 is not present in humans, this remains speculative; however, TLR-13 may have been replaced with an alternative RNA-sensing pattern recognition receptor that has the ability to recognize these RNA modifications (Oldenburg et al., 2012) .
The dissemination and acquisition of antibiotic resistance within streptococci will have a profound effect on the future of clinical therapeutics within CF disease. The recognition of 23S rRNA point mutations as a common mechanism of macrolide resistance in streptococci from this environment raises questions about whether this is an increasing mechanism of resistance or if it has been previously under-reported and overlooked in this group of organisms. Our current understanding of antibiotic resistance will need to expand to facilitate therapy in times of increasingly limited antibiotic drugs. The streptococci, in particular, may become an attractive target in clinical therapy as their role in CF patients encompasses both virulence and the sustained establishment of antibiotic resistance.
